糖基磷脂酰肌醇转酰胺酶与肝癌

doi:10.11904/j.issn.1002-3070.2021.05.013

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (5): 458-461.doi: 10.11904/j.issn.1002-3070.2021.05.013

糖基磷脂酰肌醇转酰胺酶与肝癌

贺玲综述, 姚克铖审校

湖北省宜昌市第一人民医院(宜昌 443000)

收稿日期:2021-03-19 修回日期:2021-04-07 出版日期:2021-10-28 发布日期:2021-10-25
通讯作者: 姚克铖,E-mail:yaokecheng@ctgu.edu.cn
作者简介:贺玲,女,(1986-),硕士,主治医师,从事全科医学领域的研究。
基金资助:
湖北省卫生健康科研基金资助项目(编号:WJ2021M067);宜昌市医疗卫生科研项目(编号:A21-2-024)

Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma

HE Ling, YAO Kecheng

The First People's Hospital of Yichang,Yichang 443000,China

Received:2021-03-19 Revised:2021-04-07 Online:2021-10-28 Published:2021-10-25

摘要/Abstract

摘要： 肝癌是全球癌症负担的主要来源,而肝癌中最主要的组织学类型为肝细胞癌(Hepatocellular carcinoma,HCC)。因此,阐明HCC发生发展、复发机制以及寻找新的治疗靶点成为HCC研究的重要方向。近年来越来越多的学者对糖基磷脂酰肌醇(GPI)锚定蛋白合成过程进行研究,发现参与GPI锚定蛋白合成的多个亚基的表达异常不仅参与了人类疾病的发展,也参与了人类多种肿瘤的发生发展,糖基磷脂酰肌醇转酰胺酶(Glycosylphosphatidylinositol transamidase,GPI-T)作为蛋白质转移到GPI锚的关键酶,由五个亚基组成,其中PIGU于2004年被首次证明参与了膀胱癌的发生发展,随后它的五个亚基逐渐被证实参与了HCC的发生发展。本文就GPI-T的五个亚基参与HCC发生及发展的机制进行了阐述。

关键词: 糖基磷脂酰肌醇转酰胺酶, 肝细胞癌, 磷脂酰肌醇聚糖锚定生物合成

Abstract: Liver cancer is the main source of the global cancer burden,and the most important histological type of liver cancer is hepatocellular carcinoma(HCC).Therefore,elucidating the mechanism of HCC occurrence,development,recurrence and finding new therapeutic targets have become an important direction of HCC research.In recent years,more and more scholars have studied the synthesis of glucosyl phosphatidylinositol(GPI)anchored proteins,and found that the abnormal expression of multiple subunits involved in the synthesis of GPI-anchored proteins is not only involved in the development of human disease,but also participated in the occurrence and development of a variety of human tumors.Glycosylphosphatidylinositol transamidase(GPI-T),consisting of five subunits,acts as a key enzyme for protein transfer to GPI anchors.PIGU was introduced in 2004.It was proved to be involved in the occurrence and development of bladder cancer for the first time,and then its five subunits were gradually confirmed to be involved in the occurrence and development of HCC.In this paper,five subunits of GPIT involved in the pathogenesis and development of HCC were reviewed.

Key words: Glycosylphosphatidylinositol transamidase, Hepatocellular carcinoma, Phosphatidylinositol glycan anchoring biosynthesis class

中图分类号:

R735.7

贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.

HE Ling, YAO Kecheng. Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma[J]. Journal of Practical Oncology, 2021, 35(5): 458-461.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.05.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I5/458

参考文献

1 Freddie B,Jacques F,Isabelle S,et al.Global cancer statistics 2018:GLOBOCAN estimatesof incidence and mortality worldwide for 36 cancersin 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
3 Farazi PA,DePinho RA.Hepatocellular carcinoma pathogenesis:from genes to environment[J].Nat Rev Cancer,2006,6(9):674-687.
4 Kohei K,Tatsuro S,Shu K,et al.Stability of the transamidase complex catalyzing GPI anchoring of protein[J].Biochem Biophys Res Commun,2019,512(3):584-590.
5 Dilani GG,Tamara LH.GPI transamidase and GPI anchored proteins:Oncogenes and biomarkers for cancer[J].Crit Rev Biochem Mol Biol,2013,48(5):446-464.
6 Jatin KN,Santanu D,Sana J,et al.Profiling the expression pattern of GPI transamidase complex subunits in human cancer[J].Mod Pathol,2008,21(8):979-991.
7 Santanu D,Prodipto P,Nitai DM,et al.A single nucleotide polymorphism in the human PIGK gene associates with low PIGK expression in colorectal cancer patients[J].Int J Oncol,2012,41(4):1405-1410.
8 Chinh TS,Swati Si,Birgit E,et al.Structural modelling of the lumenal domain of human GPAA1,the metallopeptide synthetase subunit of the transamidase complex,reveals zinc-binding mode and two flaps surrounding the active site[J].Biol Direct,2020,15(1):14.
9 Hiroi Y,Komuro I,Chen R,et al.Molecular cloning of human homolog of yeast Gaa1 which is required for attachment of glycosylphosphatidylinositols to proteins[J].FEBS Lett,1998,421(3):252-258.
10 Jenny CH,Siu TC,Mohini P,et al.Increased expression of glycosyl-phosphatidylinositol anchor attachment protein1(GPAA1)is associated with gene amplification in hepatocellular carcinoma[J].Int J Cancer,2006,119(6):1330-1337.
11 Peng Zh,Alison VN,Shanterian H,et al.Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma[J].J Biol Chem,2012,287(30):25230-25340.
12 Chen JZ,Xiao XR,Xin HL,et al.FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma[J].Cancer Cell Int,2020,20:196.
13 Huang YP,Jatin N,Barry T,et al.Tobacco smoke activates protein association and tyrosine phosphorylation of the GPI-Transamidase complex subunits in human cancers[J].J Epithel Biol Pharmacol,2009,2:14-22.
14 Dong QD,Dai Y,Li H,et al.EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma[J].Cancer Res,2019,79(4):819-829.
15 朱星丽,黎功.肝细胞癌表皮生长因子受体及其靶向治疗研究进展[J].中国药房,2011,14:1321-1323.
16 Guo Z,Linn JF,Wu G,et al.Cdc9111(PIG-U)is a newly discovered oncogene in human bladder cancer[J].Nat Med,2004,10(4):374-381.
17 Alexej K,Fanny K,Tjitske K,et al.Mutations in PIGU impair the function of the GPI transamidase complex,causing severe intellectual disability,epilepsy,and brain anomalies[J].Am J Hum Genet,2019,105(2):395-402.
18 Arjun S,Ashok P.Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma[J].BMC Cancer,2019,19(1):663.
19 Cao JZh,Wang PH,Chen JM,et al.PIGU overexpression adds value to TNM staging in the prognostic stratification of patients with hepatocellular carcinoma[J].Hum Pathol,2019,83:90-99.
20 Alduais S,Alduais Y,Wu X,et al.HMGB1 knock-down promoting tumor cells viability and arrest pro-apoptotic proteins via Stat3/NFkappaB in HepG2 cells[J].Biofactors,2018,44(6):570-576.
21 陈军,吴飞翔,覃思繁.WWOX与STAT3在肝细胞癌组织中的表达及相关性分析[J].实用肿瘤学杂志,2013,27(1):21-25.
22 高梦丹,张永宏,赵艳.STAT1与STAT3在肝细胞癌及肝衰竭发病机制中的作用[J].临床肝胆病杂志,2018,34(9):2017-2020.
23 Berasain C,Castillo J,Perugorria MJ,et al.Inflammation and liver cancer:new molecular links[J].Ann N Y Acad Sci,2009,1155:206-221.
24 Wu J,Sheng H,Saxena R,et al.NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy[J].Cancer Lett,2009,278(2):145-155.
25 Dou C,Cao C,Wang Z,et al.EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity[J].Oncol Rep,2016,35(6):3489-3495.
26 Liu Q,Yang P,Tu K,et al.TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression[J].Chin J Cancer Res,2014,26(4):410-417.
27 沈蔚,张家敏,毛根军,等.OPN和MMP-2在肝癌的表达及临床意义[J].实用肿瘤学杂志,2008,22(5):437-438.
28 陈薇,陈靖,游佳,等.MMP-9及glypican-3在肝癌组织中的表达及其临床病理价值[J].西安交通大学学报(医学版),2018,39(3):392-395.
29 Yuri Ch,Min J,Koeun K,et al.Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma[J].World J Gastroenterol,2020,26(42):6599-6613.
30 Xin W,Yang WJ,Zhang F,et al.PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape[J].Life Sci,2020,260:118476.
31 Karn J,Watson J,Lowe A,et al.Regulation of cell cycle duration by c-myc levels[J].Oncogene,1989,4(6):773-787.

[1]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[2]	赵凌云, 齐鲁楠, 游雪梅审校. 热休克蛋白70在肝细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 528-532.
[3]	赵孟雷. 番茄红素对人肝癌HepG2细胞增殖和凋亡的影响[J]. 实用肿瘤学杂志, 2017, 31(3): 211-216.
[4]	李世杰, 杨奕, 田玉龙, 侯继野, 刘瑞宝. TACE后残余肝癌细胞β-catenin和p28GANK的表达及意义的研究[J]. 实用肿瘤学杂志, 2016, 30(5): 430-435.
[5]	王野, 畅智慧, 赵相轩综述, 刘兆玉审校. 血清中microRNA在预测肝细胞癌患者预后作用的研究探讨[J]. 实用肿瘤学杂志, 2016, 30(2): 142-145.
[6]	李世杰综述, 刘瑞宝审校. β-catenin在肝细胞癌及乏氧微环境中的研究进展[J]. 实用肿瘤学杂志, 2013, 27(4): 372-376.
[7]	王宇超,申宝忠,张同,王丹,秦海燕. CT灌注成像对原发性肝癌介入术后疗效[J]. 实用肿瘤学杂志, 2013, 27(3): 272-277.
[8]	陈军, 吴飞翔, 覃思繁. WWOX与STAT3在肝细胞癌组织中的表达及相关性分析[J]. 实用肿瘤学杂志, 2013, 27(1): 21-25.
[9]	朱文静, 杨秀华, 郭存丽, 安婷婷, 张久维. 西洋参多糖对BABL/C小鼠肝癌肿瘤的抑制效果[J]. 实用肿瘤学杂志, 2012, 26(6): 486-489.
[10]	栾天, 佟雷, 徐威, 钟照华. MiR-122促进原发性肝细胞癌Huh-7细胞凋亡[J]. 实用肿瘤学杂志, 2012, 26(5): 428-431.
[11]	熊正平, 黄芳. 肝动脉栓塞联合三维放射治疗肝癌的疗效评价[J]. 实用肿瘤学杂志, 2012, 26(3): 246-250.
[12]	李陆鹏, 张晶岩, 于友涛, 何东风. TACE对肝细胞癌VEGF、P16表达的影响[J]. 实用肿瘤学杂志, 2011, 25(3): 228-232.
[13]	燕飞虎, 张艳桥, 王艳颖, 李志伟, 张纯慧, 娄长杰. 原发性肝细胞癌微环境中CD4⁺CD25⁺调节性T细胞分布与局部免疫的关系[J]. 实用肿瘤学杂志, 2010, 24(3): 201-203.
[14]	张益, 裘国强, 彭志海. TRADD和NF-κB在乙肝后肝硬化和肝癌中的表达及意义[J]. 实用肿瘤学杂志, 2009, 23(6): 535-537.
[15]	陈淑勤;汪晓军;高凌云;袁芳平. 原发性肝细胞癌组织中T、B淋巴细胞浸润的研究[J]. 实用肿瘤学杂志, 2007, 21(04): 328-329.

糖基磷脂酰肌醇转酰胺酶与肝癌

Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价